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SBRT. Multimodal imaging for target definition, image guidance 
techniques utilizing implanted fiducial markers, 4D-CT scanning and 
respiration management techniques have considerable improved the 
SBRT.  
In general, the approach to metastatic disease has become more 
aggressive. A number of specialties offer therapies for patients with 
liver oligo-metastases and a multidisciplinary team approach in the 
management of these patients is of utmost importance. Radiotherapy 
may be utilized for a group of patients who cannot be treated by 
surgery or RFA and the radiation oncologist should therefore be a 
member of the team. 
There is sufficient data demonstration that SBRT can be used in 
therapy of liver metastases when the constraints to critical tissues 
such as stomach, bowel and lover are respected, but there is a great 
need for randomized clinical trials to prove the efficacy of SBRT in 
treatment of oligo-metastases and for trials to explore the need for 
systemic therapy along with SBRT. It is therefore strongly encouraged 
to participate in large multi-institutional randomized trials. 
 
SP-0106   
The role of surgical resection in liver oligo-metastatic disease  
P. Naredi1 
1Sahlgrenska University Hospital, Surgery, Gothenburg, Sweden  
 
When a patient is diagnosed with liver metastases it is by definition a 
systemic disease and metastases at other sites should also be 
expected. This is also the case for the third most common cancer 
disease, colorectal cancer (CRC). Almost half of all patients with CRC 
will develop liver metastases (CLM) and approximately a fourth of 
them have only the liver as metastatic site. If the patient has no 
serious co-morbidities and 30 percent of the liver parenchyma and one 
hepatic vein can be saved there is indication for liver resection. This 
is a relative safe procedure with a postoperative mortality below five 
percent and this subpopulation of patients with CRC has a 5-year 
survival of 40-50 percent and 30 percent 10-year survival.  
The good outcome in liver resected patients is the main reason for 
follow-up with tumour markers and CT scan after surgery of the 
primary tumour. 
Neoadjuvant chemotherapy will slightly improve progression free 
survival but not overall survival. Still most patients are today offered 
neoadjuvant therapy. From a multidisciplinary perspective conversion 
therapy is important. A majority of patients with CLM will get a 
response on chemotherapy and they shall then be reconsidered for 
liver resection. The 5-year survival is as good as for patients who were 
primarily resectable. On the other hand, patients with CLM that 
progress on chemotherapy have a bad prognosis, even after liver 
resection.  
From a surgical point of view a patient might have a limited 
metastatic volume in the liver but one or more small metastases can 
be badly situated. In this case ablative techniques (radiofrequence or 
microwave ablation) or stereotactic radiotherapy can be of great 
value to complement resection of other parts of the liver. 
Even if CLM is the most common indication for liver resection of 
metastatic disease there are other cancer diseases where surgery for 
oligo-metastatic disease shall be considered. These are primarily 
neuroendocrine tumours (NET), renal cell cancer, melanoma and 
ovarian cancer. As with CLM there are no randomised studies to 
support the indication for surgery but the evidence are generated by 
comparing survival of liver resected patients with a cohort who had 
similar tumour burden but were not operated. 
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Quantitative MRI holds the promise to augment radiotherapy with 
functional imaging, which may enable improved tumor targeting, and 
more personalized treatment based on a priori characterization of 
imaging biomarkers and early assessment of treatment response.  This 
lecture emphasizes some factors of quality, validation, and 
applications of quantitative MRI metrics.  
Diffusion-weighted imaging (DWI) geometric accuracy at 3 Tesla:  
Geometric accuracy is of fundamental importance for incorporation of 
anatomic imaging into radiation therapy, yet the geometric accuracy 
of clinical DWI pulse sequences is under-emphasized.  Segmented 
echo-planar (EPI) DW imaging is an accessible solution on many pre-
clinical high-field MRI systems, providing dramatic geometric accuracy 
improvement compared to single-shot EPI-DWI at similar scan time 
and signal-to-noise.  Utilizing the RESOLVE works-in-progress package 
provided by Siemens Medical Systems, segmented EPI DWI has been 
investigated as an option for more geometrically accurate clinical DWI 
at 3T.  The geometric accuracy improvement from RESOLVE is verified 
using an in vitro prostate phantom, and applied in vivo to enable 
tumor-targeted radiation therapy treatment planning for prostate 
cancer at 3 Tesla based on DWI and T2-weighted image co-registration 
(see Figure). 
Dynamic contrast enhanced (DCE) MRI validation against DCE-CT:  
DCE-MRI has broad appeal as a clinical biomarker for radiation 
oncology, yet presents with known limitations to accuracy and 
precision.  These known limitations apply to both vessel-based 
measurements of arterial input function (AIF) and tumor-based 
measurements of permeability and perfusion.  Methodologic 
improvements have been incorporated at 3 Tesla and tested against 
the standard of DCE-CT.  First, a multi-modal DCE-MRI/CT flow 
phantom has been applied to investigate factors affecting AIFs 
measured using the MRI magnitude signal, and to validate AIFs 
measured using the MRI signal phase.  Second, a 4D temporal 
segmentation (TDS) method, which enables voxel-based, parametric 
analysis based on patient-specific dynamic behaviour of contrast flow, 
has been implemented to facilitate tissue-level analysis.  Preliminary 
testing has compared DCE-CT supported by 4D-TDS to standard DCE-
MRI analysis for the detection of early changes in brain tumor 
perfusion following radiosurgery. 
Stromal imaging:  Hedgehog (Hh) pathway inhibition is a potential 
strategy to overcome treatment resistance and repopulation in 
patients undergoing radiotherapy and concurrent chemotherapy, and 
it is now widely held that the Hh pathway promotes tumor growth 
indirectly through paracrine effects on the stroma.  MRI biomarkers to 
monitor Hh inhibition and stromal depletion have been investigated in 
murine models of human cervical, pancreatic, and breast cancer, 
utilizing the 7 Tesla MRI of the STTARR facility, with emphasis on DCE-
MRI, magnetization transfer, and DWI.   
Figure: A prostate DWI geometric distortion phantom, consisting of 
distilled water within concentric acrylic cylinders of 3, 6, and 12 cm 
(e.g. corresponding to the outer diameter of the Hologic endorectal 
coil diameter; the anterior peripheral zone; and the anterior prostate) 
was imaged with RESOLVE and standard DWI at 3 T (1.4x.1.4x3-mm 
resolution, 28 slices). (a, b) Meshes of cylinder boundaries for 
RESOLVE and standard DWI were generated, and cylinder boundaries 
were tracked to quantify vertical distortion in the phase encoding 
direction. Compared to standard DWI, RESOLVE reduced the mean RMS 
displacement of inner and middle cylinders 3-fold (to 0.5 mm) and 
reduced the maximum distortion in y from 13 to 3 mm. (c-d) clinical 
prostate RESOLVE and standard DWI ADC maps at 3T in matched 
slices, verifying distortion reduction in vivo in approximately 
equivalent scan times and matched spatial resolution (1.4x1.4x3-mm 
voxels). 
 
  
   
 
 
 
